News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Actelion Ltd. Board Seeks Rejection of Elliott Plan; Says Elliot Wants to Force Quick Sale
March 28, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, March 28 (Reuters) - The board of Actelion (ATLN.VX) urged shareholders on Monday to reject what it called an ill-conceived plan by activist hedge fund Elliott Advisors to install six new board members and prepare the way for a sale.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Neuroscience
Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy
September 8, 2025
·
2 min read
·
Tristan Manalac
IPO
SPACs Line Up To Clear Biotech’s IPO Backlog
September 3, 2025
·
6 min read
·
Annalee Armstrong
IPO
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute
September 3, 2025
·
3 min read
·
Annalee Armstrong
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
September 2, 2025
·
2 min read
·
Heather McKenzie